As per the latest market research conducted by FMI, the global medical nitroglycerin sprays market is expected to record a CAGR of 3.9% from 2023 to 2033. In 2023, the market size is projected to reach a valuation of US$ 110.9 million. By 2033, the valuation is expected to reach US$ 163.5 million.
Those with coronary artery disease who experience angina attacks (chest discomfort) can be treated with nitroglycerin lingual spray, which is primarily driving the growth of the nitroglycerin lingual spray market.
To stop angina attacks from occurring, the nitroglycerin lingual spray may also be used just before potential triggers. The category of medications known as vasodilators includes nitroglycerin. A spray of nitroglycerin is available for application on or under the tongue. Typically, the spray is applied as needed, either 5 to 10 minutes before activities that may cause angina episodes or at the first sign of an attack.
Crucial Growth Factors of the Medical Nitroglycerin Sprays Market:
Economical and No Side Effects:
The spray of nitroglycerin is considered economical and easily accessible. Also, compared to other drugs, it has superior therapeutic effects. It has fewer side effects than traditional medications. In the upcoming years, these reasons are expected to propel the market for nitroglycerin spray.
Available in Different Variations:
Several dose forms of medical nitroglycerin are available in the market, including sublingual tablets, nitroglycerin oral sprays, in-vitro patches, ointments, nitroglycerin mouth sprays, and patches. Owing to this the nitroglycerin oral sprays market as well as the nitroglycerin mouth sprays market is expected to expand. For instance, nitroglycerin sprays come in a variety of bottle sizes, with contents ranging from 60 doses to 240 doses. Throughout the forecast period, the availability of nitroglycerin spray in a variety of dosage forms and capacities is anticipated to drive the global market.
According to the World Health Organization, the population of adults who are 60 years and above is expected to increase from 900 million in 2015 to 2 billion by 2050. The risk of coronary vascular disease is often very high in the elderly population. Thus, it is projected that growth in the elderly population is likely to propel the nitroglycerin spray market.
| Attributes | Value |
|---|---|
| Medical Nitroglycerin Sprays Value (2022) | US$ 106.3 million |
| Medical Nitroglycerin Sprays Market Expected Value (2023) | US$ 110.9 million |
| Medical Nitroglycerin Sprays Market Forecast Value (2033) | US$ 163.5 million |
| Medical Nitroglycerin Sprays Market Expected CAGR (2023 to 2033) | 3.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to reports, nitroglycerin-treated patients with microvascular angina do not even appear to have made any noticeable advancements. This is because nitroglycerin formulations seem to have a strong resistance to tiny blood arteries. They can drop blood pressure, which may cause difficulties.
Prolonged migraines are a significant cause for concern for migraine sufferers who take more nitroglycerin. For the coming ten years, both of the aforementioned issues are anticipated to stifle growth prospects.
Principal Consultant
The medical nitroglycerin sprays market recorded a CAGR of 3.8% from 2018 to 2022. The market reached a valuation of US$ 106.3 million in 2022. On the other hand, as per the latest market research conducted by FMI, the global medical nitroglycerin sprays market is expected to record a CAGR of 3.9% from 2023 to 2033.
In 2023, the market size is projected to reach a valuation of US$ 110.9 million. By 2033, the valuation is expected to be worth US$ 163.5 million. Nitroglycerin spray is used to treat angina or chest pain in people with cardiovascular disease. To avoid angina attacks, it is sometimes administered just before activities that could set them off. A vasodilator is a class of medication that includes nitroglycerin. It works by relaxing the blood vessels, which limits the work the heart must do and consequently reduces the need for oxygen.
Sales of Medical Nitroglycerin Sprays are Likely to be Driven by an Increase in the Prevalence of Angina Pectoris
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
There are numerous dosage forms for medical nitroglycerin, including sublingual pills, in-vitro, sprays, patch therapy, and balms. Also, there are numerous bottle sizes for nitroglycerin sprays, ranging from 60 to 230 dosages. Moreover, they are less harmful than conventional medicines in terms of side effects. The aforementioned traits are projected to offer considerable opportunities for market expansion during the forecast period.
The Demand for Medical Nitroglycerin Sprays is Likely to be Driven by the Rising Prevalence of Coronary Heart Disease in the United States
For the past ten years, the pharmaceutical business in the United States has experienced rapid growth. Companies like Perrigo Company plc, Evus Health Solutions, and Arimax Pharmaceuticals are well-established in the United States.
An increase in the prevalence of coronary heart disease, which produces acute angina pectoris and calls for the incorporation of efficient treatment techniques, is chiefly responsible for its rise in the country.
Growth in Sales of Medical Nitroglycerin Spray is Likely to be Driven by Growing Healthcare Facilities & Increasing Incidence of Cardiovascular Diseases in Saudi Arabia
Due to an increase in the prevalence of non-communicable diseases and improved healthcare facilities, Saudi Arabia's demand for pharmaceutical products is rising. MNCs own a substantial share of the medicine market in Saudi Arabia, which is expected to be dominated by MNCs in the coming future.
In the upcoming years, it is anticipated that rising cardiovascular disorder incidence, rising healthcare spending, and rising health consciousness are all expected to contribute to the market expansion for medical nitroglycerin sprays.
Growth Outlook of Country-wise Insights:
| Country | United States |
|---|---|
| CAGR (2018 to 2022) | 4.1% |
| CAGR (2023 to 2033) | 4.1% |
| Valuation (2033) | US$ 63.1 million |
| Country | United Kingdom |
|---|---|
| CAGR (2018 to 2022) | 3.4% |
| CAGR (2023 to 2033) | 3.9% |
| Valuation (2033) | US$ 7 million |
| Country | China |
|---|---|
| CAGR (2018 to 2022) | 4.1% |
| CAGR (2023 to 2033) | 4.0% |
| Valuation (2033) | US$ 11.1 million |
| Country | Germany |
|---|---|
| CAGR (2018 to 2022) | 4.2% |
| CAGR (2023 to 2033) | 4.3% |
| Valuation (2033) | US$ 11.5 million |
| Country | Canada |
|---|---|
| CAGR (2018 to 2022) | 2.7% |
| CAGR (2023 to 2033) | 4.4% |
| Valuation (2033) | US$ 10.6 million |
High Usage of Medicinal Nitroglycerin Sprays for Angina Pectoris Prophylaxis
Medicinal nitroglycerin sprays are anticipated to be used frequently for the prevention of angina pectoris. Prophylaxis of the Angina Pectoris segment is expected to record a CAGR of 3.9% over the forecast period.
On the other hand, the acute alleviation of attack (therapy) category recorded a CAGR of 12.9% in 2022. Rising prevalence of acute angina pectoris and the resulting trauma that patients experience are expected to drive this market to new heights in the future.
The primary objectives of significant market players are to expand their product lines and strengthen their portfolios. To increase their customer base, these businesses are concentrating on introducing generic products with low prices and safety features.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ million for Value, Units for Volume |
| Key Regions Covered |
|
| Key Countries Covered |
|
| Key Market Segments Covered |
|
| Key Companies Profiled |
|
| Pricing | Available upon Request |
By 2033, the market will expand at a 3.9% CAGR.
The 2023 market value is US$ 110.9 million.
From 2018 to 2022, the market expanded at a 3.8% CAGR.
By 2033, the market will reach US$ 163.5 million.
Troikaa, Perrigo Company Plc., and Dalmia Bros. Pvt. Ltd. are some key players.
1. Executive Summary | Medical Nitroglycerin Sprays Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033
5.3.1. Prophylaxis of Angina Pectoris
5.3.2. Acute Relief of Attack
5.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dose Capacity
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Dose Capacity, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dose Capacity, 2023 to 2033
6.3.1. 60 Metered Sprays/Bottles
6.3.2. 90 Metered Sprays/Bottles
6.3.3. 200 Metered Sprays/Bottles
6.3.4. 230 Metered Sprays/Bottles
6.4. Y-o-Y Growth Trend Analysis By Dose Capacity, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Dose Capacity, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Application
9.2.3. By Dose Capacity
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Application
9.3.3. By Dose Capacity
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Application
10.2.3. By Dose Capacity
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Application
10.3.3. By Dose Capacity
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Application
11.2.3. By Dose Capacity
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Application
11.3.3. By Dose Capacity
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Application
12.2.3. By Dose Capacity
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Application
12.3.3. By Dose Capacity
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Application
13.2.3. By Dose Capacity
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Application
13.3.3. By Dose Capacity
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Application
14.2.3. By Dose Capacity
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Application
14.3.3. By Dose Capacity
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Application
15.2.3. By Dose Capacity
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Application
15.3.3. By Dose Capacity
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Application
16.1.2.2. By Dose Capacity
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Application
16.2.2.2. By Dose Capacity
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Application
16.3.2.2. By Dose Capacity
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Application
16.4.2.2. By Dose Capacity
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Application
16.5.2.2. By Dose Capacity
16.5.2.3. By Distribution Channel
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Application
16.6.2.2. By Dose Capacity
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Application
16.7.2.2. By Dose Capacity
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Application
16.8.2.2. By Dose Capacity
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Application
16.9.2.2. By Dose Capacity
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Application
16.10.2.2. By Dose Capacity
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Application
16.11.2.2. By Dose Capacity
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Application
16.12.2.2. By Dose Capacity
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Application
16.13.2.2. By Dose Capacity
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Application
16.14.2.2. By Dose Capacity
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Application
16.15.2.2. By Dose Capacity
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Application
16.16.2.2. By Dose Capacity
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Application
16.17.2.2. By Dose Capacity
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Application
16.18.2.2. By Dose Capacity
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Application
16.19.2.2. By Dose Capacity
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Application
16.20.2.2. By Dose Capacity
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Application
16.21.2.2. By Dose Capacity
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Application
17.3.3. By Dose Capacity
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Perrigo Company Plc.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Evus Health Solutions LLC.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. G. Pohl-Boskamp GmbH & Co.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Akrimax Pharmaceuticals LLC
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Glenmark Pharmaceuticals Ltd
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Dalmia Bros. Pvt. Ltd.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Troikaa
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. ESPERO BIOPHARMA, INC
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Square Pharmaceuticals Ltd
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Sun Pharmaceutical Industries Ltd.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Medical Nitroglycerin Sprays Market
